Immatics (NASDAQ: IMTX) lines up four oral cancer therapy talks for ASCO 2026

Rhea-AI Filing Summary

Immatics N.V. filed a report noting that all of its submitted scientific abstracts were selected for oral presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The Company will deliver four talks covering both its PRAME-directed T-cell therapies and its T-cell receptor-based bispecifics.

Presentations will highlight patient-level response data in advanced melanoma for anzutresgene autoleucel (anzu-cel), Phase 1 results for IMA203CD8 in ovarian cancer, Phase 1 PRAME T-cell therapy data in synovial sarcoma, and first-in-human results for the MAGEA4/8 bispecific IMA401 in recurrent or refractory solid tumors. Immatics positions itself as a global leader in precision targeting of PRAME across multiple cancer indications.

Key Figures

Number of oral presentations: 4 presentations ASCO 2026 meeting dates: May 29–June 2, 2026 Melanoma session time: 8:00–11:00 am CDT +5 more

8 metrics

Number of oral presentations 4 presentations Immatics abstracts selected for oral talks at ASCO 2026

ASCO 2026 meeting dates May 29–June 2, 2026 Annual oncology conference in Chicago, Illinois, USA

Melanoma session time 8:00–11:00 am CDT Anzu-cel (IMA203) advanced melanoma oral session on June 1, 2026

IMA203CD8 ovarian cancer session 8:00–9:30 am CDT Rapid oral gynecologic cancer session on May 30, 2026

Synovial sarcoma session 4:30–6:00 pm CDT Rapid oral sarcoma session on May 31, 2026

IMA401 immunotherapy session 8:00–11:00 am CDT Developmental Therapeutics – Immunotherapy session on May 31, 2026

Melanoma abstract ID 9508 Anzu-cel advanced melanoma oral abstract

IMA401 abstract ID 2507 First-in-human IMA401 bispecific solid tumor study

Key Terms

PRAME, T-cell receptor (TCR) T-cell therapy, bispecific T-cell engager (TCER), forward-looking statements, +2 more

6 terms

PRAME medical

"the global leader in precision targeting of PRAME with multiple clinical-stage programs"

T-cell receptor (TCR) T-cell therapy medical

"a PRAME-directed T-cell receptor (TCR) T-cell therapy"

bispecific T-cell engager (TCER) medical

"a MAGEA4/8 targeted T-cell receptor-based bispecific T-cell engager (TCER)"

forward-looking statements regulatory

"Certain statements in this press release may be considered forward-looking statements."

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

foreign private issuer regulatory

"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

solid tumors medical

"developing novel immunotherapies for patients with solid tumors."

Solid tumors are abnormal masses of tissue that form when cells in organs or glands grow uncontrollably, like a dense knot in a garden plant rather than something spread through the water. For investors, they matter because treatments, diagnostics and surgeries targeting solid tumors drive large clinical programs, regulatory reviews and potential revenue streams; success or failure in treating these tumors can significantly affect a company’s drug pipeline, valuation and market opportunity.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

April 21, 2026

Commission File Number: 001-39363

IMMATICS N.V.

Paul-Ehrlich-Straße 15

72076 Tübingen, Federal Republic of Germany

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On April 21, 2026, Immatics N.V. (the “Company”) issued a press release announcing that all submitted abstracts have been selected for oral presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held from May 29-June 2, 2026, in Chicago, Illinois.

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press release dated April 21, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	IMMATICS N.V.
Date: April 21, 2026
	By:	/s/ Harpreet Singh
	Name:	Harpreet Singh
	Title:	Chief Executive Officer

Exhibit 99.1

 

PRESS RELEASE

Immatics Announces Four Upcoming Oral Presentations

Across Its Clinical Cell Therapy and Bispecific Portfolio
at 2026 ASCO Annual Meeting

Houston, Texas and Tuebingen, Germany, April 21, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced all submitted abstracts have been selected for oral presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held from May 29-June 2, 2026, in Chicago, Illinois, USA.

The four oral presentations will include

· Phase 1b clinical data on anzu-cel, the Company’s lead PRAME cell therapy, in advanced cutaneous and uveal melanoma with a focus on characterizing response dynamics

· Updated Phase 1a dose-escalation and Phase 1b dose-expansion data for the second-generation (GEN2) PRAME cell therapy candidate, IMA203CD8, in gynecologic cancers at clinically relevant dose levels, which could support its development toward a tumor-agnostic approach

· Updated Phase 1 data on PRAME cell therapies in synovial sarcoma, further demonstrating the potential to address diverse tumor types beyond melanoma and gynecologic cancers

· Updated results for the MAGEA4/8 bispecific, IMA401, across multiple cancers, highlighting its potential as part of a combination approach with the Company’s PRAME bispecific, IMA402, aimed at synergistic activity and expanded patient reach

Together, these data underscore the continued advancement of Immatics’ PRAME franchise and its focus on developing novel immunotherapies for patients with solid tumors.

Full abstracts will be available on the ASCO website on May 21, 2026, at 5:00 pm ET.

Details on Oral Presentations

PRAME Cell Therapies: Anzu-cel (IMA203) and IMA203CD8 (GEN2)

Title: Patient-level clinical response dynamics in advanced melanoma with anzutresgene autoleucel (anzu-cel), a PRAME-directed T-cell receptor (TCR) T-cell therapy

Presenting author: Davar Diwakar, MD

Session: Oral Abstract Session - Melanoma/Skin Cancers

Immatics Press Release April 21, 2026 1 | 3

 

Date / Time: June 1, 2026 / 8:00 – 11:00 am CDT

Abstract ID: 9508

Title: Phase 1a study results for IMA203CD8, a PRAME-directed T-cell receptor (TCR) T-cell therapy, in ovarian cancer

Presenting author: Antonia Busse, MD

Session: Rapid Oral Abstract Session – Gynecologic Cancer

Date / Time: May 30, 2026 / 8:00 – 9:30 am CDT

Abstract ID: 5509

Title: Phase 1 study results with PRAME-directed T-cell receptor (TCR) T-cell therapies in synovial sarcoma

Presenting author: Dejka M. Araujo, MD

Session: Rapid Oral Abstract Session - Sarcoma

Date / Time: May 31, 2026 / 4:30 – 6:00 pm CDT

Abstract ID: 11516

MAGEA4/8 Bispecific: IMA401

Title: First-in-human results with IMA401, a MAGEA4/8 targeted T-cell receptor-based bispecific T-cell engager (TCER), in recurrent or refractory solid tumors

Presenting author: Martin Wermke, MD

Session: Developmental Therapeutics – Immunotherapy

Date / Time: May 31, 2026 / 8:00 – 11:00 am CDT

Abstract ID: 2507

About Immatics

Immatics is committed to making a meaningful impact on the lives of patients with cancer. We are the global leader in precision targeting of PRAME, a target expressed in more than 50 cancers. Our cutting-edge science and robust clinical pipeline form the broadest PRAME franchise with the most PRAME indications and modalities, spanning TCR T-cell therapies and TCR bispecifics.

Immatics intends to use its website www.immatics.com as a means of disclosing material non-public information. For regular updates, you can also follow us on LinkedIn and Instagram.

Forward-Looking Statements

Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or the Company’s future financial or operating performance. For example, statements concerning timing of data read-outs for product candidates, the timing, outcome and design of clinical trials, the nature of clinical trials (including whether such clinical trials will be registration-enabling), the timing and outcomes of

Immatics Press Release April 21, 2026 2 | 3

 

IND, CTA or BLA filings, estimated market opportunities of product candidates, the Company’s focus on partnerships to advance its strategy, and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “plan”, “target”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in the Company’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission (SEC). Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. The Company undertakes no duty to update these forward-looking statements. All the scientific and clinical data presented within this press release are – by definition prior to completion of the clinical trial and a clinical study report – preliminary in nature and subject to further quality checks including customary source data verification.

For more information, please contact:

Media

Trophic Communications

Phone: +49 151 74416179

immatics@trophic.eu

Immatics N.V.

Jordan Silverstein

Head of Strategy

Phone: +1 346 319-3325

InvestorRelations@immatics.com

Immatics Press Release April 21, 2026 3 | 3

FAQ

What did Immatics (IMTX) announce in its latest 6-K filing?

Immatics reported that all submitted abstracts were accepted for oral presentation at the 2026 ASCO Annual Meeting. Four talks will cover its PRAME-directed T-cell therapies and the MAGEA4/8 bispecific IMA401, showcasing early clinical data across multiple solid tumor indications.

How many Immatics presentations will be given at the 2026 ASCO meeting?

Immatics will deliver four oral presentations at the 2026 ASCO Annual Meeting. These include three talks on PRAME-directed T-cell receptor T-cell therapies and one on IMA401, a MAGEA4/8-targeted T-cell receptor-based bispecific T-cell engager in recurrent or refractory solid tumors.

Which Immatics PRAME cell therapy programs are featured at ASCO 2026?

The PRAME programs featured are anzutresgene autoleucel (anzu-cel, also called IMA203) and IMA203CD8. Presentations cover patient-level response dynamics in advanced melanoma, Phase 1a results in ovarian cancer, and Phase 1 data in synovial sarcoma, highlighting multiple solid tumor settings.

What is Immatics’ bispecific candidate IMA401 that will be presented at ASCO?

IMA401 is a MAGEA4/8-targeted, T-cell receptor-based bispecific T-cell engager (TCER). At ASCO 2026, Immatics will present first-in-human results in patients with recurrent or refractory solid tumors, within the Developmental Therapeutics – Immunotherapy session on May 31, 2026.

When and where will the 2026 ASCO presentations involving Immatics take place?

The ASCO Annual Meeting runs from May 29 to June 2, 2026, in Chicago. Immatics’ oral sessions occur on May 30, May 31, and June 1 at various morning and afternoon time slots, each tied to specific cancer-focused abstract sessions.

What therapeutic focus does Immatics highlight in this announcement?

Immatics emphasizes its leadership in precision targeting of PRAME, a cancer-associated target expressed in many tumors. The company’s portfolio spans T-cell receptor T-cell therapies and T-cell receptor bispecifics, aiming to develop novel immunotherapies for a broad range of solid cancers.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 18.0 KB